APOC3 and metabolic syndrome: In transgenic mice that overexpress human APOC3, the resulting elevation of TRLs such as VLDL induces hypertriglyceridemia, closely mirroring the dyslipidemia observed in humans and its associated cardiovascular risks due to TG accumulation in the bloodstream [120,122].